Volume 3, Issue 4
Editorialp. 445
Therapy for atrial fibrillation: new challenges
Author(s): Eduard Shantsila, Timothy Watson and Gregory YH Lip
Bulletin Boardp. 449
Bulletin Board: Volume 3 Issue 4
Drug Evaluationp. 453
Deferasirox: a novel, once-daily oral iron chelator
Author(s): Maria Domenica Cappellini
Drug Evaluationp. 461
Dalteparin sodium in the management of thromboembolic disorders
Author(s): Agnes YY Lee
Drug Evaluationp. 475
Tegaserod in the treatment of constipation-predominant functional gastrointestinal disorders
Author(s): Anurag Agrawal and Peter Whorwell
Drug Evaluationp. 485
Solifenacin: a novel drug licensed for the treatment of overactive bladder and detrusor overactivity
Author(s): Jean-Jacques Wyndaele
Case Reportp. 495
High-dose methotrexate complicated by acute tubular necrosis: a case report
Author(s): Myke R Green, Sajeel A Chowdhary, Lisa M Chalmers, Kris M Lombardi and Marc C Chamberlain
Research Articlep. 499
Lymphoma of bone: a review of 140 patients
Author(s): Henry J Mankin, Francis J Hornicek, David C Harmon and Mark C Gebhardt
Research Articlep. 509
Randomized controlled trial of the effect of hysterectomy or LNG-IUS use on bone mineral density: a five-year follow-up
Author(s): Karoliina H Halmesmaki, Jorma A Paavonen, Marjo T Tuppurainen and Ritva A Hurskainen
Research Articlep. 517
Angioplasty versus stenting for cardiac allograft vasculopathy
Author(s): Robert S Dieter, Greg M Gauthier, Aravinda Nanjundappa and Matthew R Wolff
Research Articlep. 521
Experimental model of reversible myelosuppression caused by shortterm, high-dose oxazolidinone administration
Author(s): Emily J Hickey, CJ Gill, AS Misura, AF Flattery and GK Abruzzo
Review Articlep. 527
Overcoming and containing bacterial resistance: appropriate antibiotic use in community-acquired RTIs
Author(s): Stephen Brunton
Appendicesp. 546
Glossary: Volume 3 Issue 4
Appendicesp. 547
Appendices: Volume 3 Issue 4
Appendicesp. 552
